Anika Therapeutics, Inc. Business Combination, Acquisition Related Costs
Anika Therapeutics, Inc. (ANIK) reported Business Combination, Acquisition Related Costs of $2.15 million for the 12-month period ending 2009-12-31, per its 10-K filed 2012-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2012-03-13
- Anika Therapeutics, Inc. business combination, acquisition related costs for fiscal 2009 was $2.15M.
| Period end | Business Combination, Acquisition Related Costs 12 month |
|---|---|
| 2009-12-31 | $2.15M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |